BioSpace News Archive

Positron Corporation, a nuclear medicine PET imaging device systems and clinical services company, is pleased to announce that the Company has retained Medical Device Academy ”MDA”) as its consultant for the Company’s new PET/CT device 510K submission with the Food and Drug Administration.

EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, announced the launch of its new Slim Pack fertility medication packaging, reduced in size for convenience and environmental impact.

MDxHealth SA, a commercial-stage precision diagnostics company, announced it will release its financial results for the fourth quarter and full year ended December 31, 2021, after market close on Wednesday, March 2, 2022.

Relay Therapeutics, Inc., a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report fourth quarter and full year 2021 financial results and corporate highlights after the close of market on Thursday, February 24, 2022.

Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, announced the appointment of Michael J. Driscoll, Ed.D. to the Company’s Board of Directors, effective February 15, 2022.

Prothena Corporation plc, a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, reported financial results for the fourth quarter and full year 2021.

Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy to treat complex calcified cardiovascular disease, reported financial results for the three months and full year ended December 31, 2021.

Beta Bionics, Inc. — a clinical stage medical technology company committed to the design, development, and commercialization of the iLet® Bionic Pancreas System — announced the completion of a $57 million Series C equity financing.

AVITA Medical, Inc. announced that the United States Food and Drug Administration has reviewed and approved the premarket approval application supplement for RECELL® Autologous Cell Harvesting Device, an enhanced RECELL System aimed at providing clinicians a more efficient user experience and simplified workflow.

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, before the opening of the U.S. financial markets.